Viking Therapeutics (VKTX) Stock Forecast, Price Target & Predictions
VKTX Stock Forecast
Viking Therapeutics stock forecast is as follows: an average price target of $100.50 (represents a 50.61% upside from VKTX’s last price of $66.73) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
VKTX Price Target
The average price target for Viking Therapeutics (VKTX) is $100.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $138.00 to $15.00. This represents a potential 50.61% upside from VKTX's last price of $66.73.
VKTX Analyst Ratings
According to 8 Wall Street analysts, Viking Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VKTX stock is 1 'Strong Buy' (12.50%), 7 'Buy' (87.50%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Viking Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 27, 2024 | Michael Ulz | Morgan Stanley | $105.00 | $47.39 | 121.57% | 57.35% |
| Jun 25, 2024 | Joseph Pantginis | H.C. Wainwright | $90.00 | $52.12 | 72.68% | 34.87% |
| May 16, 2024 | Steve Seedhouse | Raymond James | $116.00 | $69.06 | 67.97% | 73.83% |
| May 16, 2024 | Joon Lee | Truist Financial | $120.00 | $69.53 | 72.60% | 79.83% |
| Mar 26, 2024 | Jay Olson | Oppenheimer | $138.00 | $80.83 | 70.73% | 106.80% |
| Mar 26, 2024 | Justin Zelin | BTIG | $125.00 | $83.98 | 48.84% | 87.32% |
| Mar 26, 2024 | Samimy Annabel | Stifel Nicolaus | $95.00 | $83.87 | 13.27% | 42.36% |
| Mar 15, 2024 | Justin Zelin | BTIG | $100.00 | $62.56 | 59.85% | 49.86% |
| Dec 24, 2022 | Maxim Maxim | Maxim Group | $15.00 | $8.45 | 77.51% | -77.52% |
| Dec 19, 2022 | Justin Zelin | BTIG | $20.00 | $6.72 | 197.57% | -70.03% |
The latest Viking Therapeutics stock forecast, released on Jun 27, 2024 by Michael Ulz from Morgan Stanley, set a price target of $105.00, which represents a 121.57% increase from the stock price at the time of the forecast ($47.39), and a 57.35% increase from VKTX last price ($66.73).
Viking Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 8 |
| Avg Price Target | - | $97.50 | $111.13 |
| Last Closing Price | $66.73 | $66.73 | $66.73 |
| Upside/Downside | -100.00% | 46.11% | 66.54% |
In the current month, the average price target of Viking Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Viking Therapeutics's last price of $66.73. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Sep 11, 2024 | William Blair | Outperform | Outperform | Hold |
| Jul 25, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Jul 05, 2024 | BTIG | Buy | Buy | Hold |
| Jun 27, 2024 | Morgan Stanley | - | Overweight | Initialise |
| Jun 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 16, 2024 | Raymond James | - | Strong Buy | Upgrade |
| Mar 26, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Mar 26, 2024 | BTIG | Buy | Buy | Hold |
| Mar 29, 2023 | BTIG | Buy | Buy | Hold |
Viking Therapeutics's last stock rating was published by Morgan Stanley on Sep 12, 2024. The company gave VKTX a "Overweight" rating, the same as its previous rate.
Viking Therapeutics Financial Forecast
Viking Therapeutics Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.64M | $1.06B | $1.67B | $185.40M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.17M | $1.28B | $2.00B | $222.48M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.11M | $851.78M | $1.33B | $148.32M |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9 | 8 | 11 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Viking Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VKTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Viking Therapeutics EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9 | 8 | 11 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.29M | $-4.79M | $-3.17M | $-7.59M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-4.39M | $-3.10M | $-3.70M | $-42.59M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.51M | $-2.48M | $-2.96M | $-34.07M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.27M | $-3.72M | $-4.44M | $-51.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 1.55% | 0.86% | 0.18% |
undefined analysts predict VKTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Viking Therapeutics's previous annual EBITDA (undefined) of $NaN.
Viking Therapeutics Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9 | 8 | 11 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.55M | $-5.22M | $-3.59M | $-7.87M |
| Avg Forecast | $-53.58M | $-52.52M | $-46.62M | $-38.97M | $-32.02M | $-31.90M | $-30.90M | $-30.76M | $-44.11M | $-42.09M | $-38.26M | $-34.33M | $-30.16M | $-26.43M | $-28.99M | $-4.73M | $-3.38M | $-4.18M | $-44.10M |
| High Forecast | $-53.58M | $-52.52M | $-46.62M | $-38.97M | $-32.02M | $-31.90M | $-30.90M | $-30.76M | $-44.11M | $-42.09M | $-38.26M | $-34.33M | $-30.16M | $-23.13M | $-28.99M | $-3.79M | $-2.70M | $-3.35M | $-35.28M |
| Low Forecast | $-53.58M | $-52.52M | $-46.62M | $-38.97M | $-32.02M | $-31.90M | $-30.90M | $-30.76M | $-44.11M | $-42.09M | $-38.26M | $-34.33M | $-30.16M | $-34.14M | $-28.99M | $-5.68M | $-4.05M | $-5.02M | $-52.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 1.55% | 0.86% | 0.18% |
Viking Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VKTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Viking Therapeutics SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9 | 8 | 11 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.76M | $1.44M | $1.39M | $1.53M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.35M | $932.10K | $1.62M | $8.56M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.82M | $1.12M | $1.95M | $10.27M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.88M | $745.68K | $1.30M | $6.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 1.55% | 0.86% | 0.18% |
Viking Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to VKTX last annual SG&A of $1.76M (Mar 18).
Viking Therapeutics EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9 | 8 | 11 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.08 | $-0.23 | $-0.40 | $-1.07 |
| Avg Forecast | $-0.49 | $-0.48 | $-0.42 | $-0.35 | $-0.29 | $-0.29 | $-0.28 | $-0.28 | $-0.40 | $-0.38 | $-0.35 | $-0.31 | $-0.27 | $-0.24 | $-0.26 | $-0.16 | $-0.11 | $-0.56 | $-0.73 |
| High Forecast | $-0.49 | $-0.48 | $-0.42 | $-0.35 | $-0.29 | $-0.29 | $-0.28 | $-0.28 | $-0.40 | $-0.38 | $-0.35 | $-0.31 | $-0.27 | $-0.21 | $-0.26 | $-0.13 | $-0.09 | $-0.45 | $-0.58 |
| Low Forecast | $-0.49 | $-0.48 | $-0.42 | $-0.35 | $-0.29 | $-0.29 | $-0.28 | $-0.28 | $-0.40 | $-0.38 | $-0.35 | $-0.31 | $-0.27 | $-0.31 | $-0.26 | $-0.19 | $-0.13 | $-0.67 | $-0.87 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.50% | 2.09% | 0.71% | 1.47% |
According to undefined Wall Street analysts, Viking Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VKTX previous annual EPS of $NaN (undefined).
Viking Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| VKTX | Viking Therapeutics | $66.73 | $100.50 | 50.61% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| SRPT | Sarepta Therapeutics | $124.65 | $169.93 | 36.33% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| PTCT | PTC Therapeutics | $33.99 | $44.33 | 30.42% | Hold |
| AXSM | Axsome Therapeutics | $93.67 | $117.83 | 25.79% | Buy |
| MCRB | Seres Therapeutics | $1.00 | $1.25 | 25.00% | Buy |
VKTX Forecast FAQ
Is Viking Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, Viking Therapeutics (VKTX) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of VKTX's total ratings.
What is VKTX's price target?
Viking Therapeutics (VKTX) average price target is $100.5 with a range of $15 to $138, implying a 50.61% from its last price of $66.73. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Viking Therapeutics stock go up soon?
According to Wall Street analysts' prediction for VKTX stock, the company can go up by 50.61% (from the last price of $66.73 to the average price target of $100.5), up by 106.80% based on the highest stock price target, and down by -77.52% based on the lowest stock price target.
Can Viking Therapeutics stock reach $100?
VKTX's average twelve months analyst stock price target of $100.5 supports the claim that Viking Therapeutics can reach $100 in the near future.
What are Viking Therapeutics's analysts' financial forecasts?
Viking Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-126M (high $-126M, low $-126M), average SG&A $0 (high $0, low $0), and average EPS is $-1.138 (high $-1.138, low $-1.138). VKTX's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-192M (high $-192M, low $-192M), average SG&A $0 (high $0, low $0), and average EPS is $-1.737 (high $-1.737, low $-1.737).